Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,076.77
(
-0.49%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
101.37
(
4.80%
)
Bitcoin
77,906.24
(
-0.42%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: r622102675 post# 173382

Wednesday, 04/16/2014 5:57:07 PM

Wednesday, April 16, 2014 5:57:07 PM

Post# of 347009
thanks R622! I should have remembered to read that complaint over again.... this story has too much info.

The interesting part would be if Abbott actually ever tried to reduce their original offer for the partnership signing after all hell broke loose. I do find it interesting that they are setting up for Phase III NSCLC.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote